XGEVA 120mg Price

Overview

Welcome to Dwaey, specifically on XGEVA 120mg Injection/Solution for page.
This medicine contains an important and useful components, as it consists of Denosumab.
XGEVA 120mg is available in the market in concentration 120mg/Vial and in the form of Injection/Solution for.

AMGEN EUROPE B.V. is the producer of XGEVA 120mg and it is imported from NETHERLANDS, The most popular alternatives of XGEVA 120mg are listed downward .

Mode Of Action

Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to receptor activator of nuclear factor kappa-B ligand (RANKL) preventing RANKL from activating its only receptor, RANK, on the surface of osteoclasts and their precursors, independent of bone surface. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function and survival. Denosumab therefore reduces bone resorption and increases bone mass and strength in both cortical and trabecular bone.

Indication

• Postmenopausal Osteoporosis

Precaution

Correct hypocalcemia prior to initiation of therapy. Patients should receive Ca & vit D supplements during treatment (unless hypercalcemia is present). Skin infections predominantly cellulitis may develop. Osteonecrosis of the jaw in patients w/ advanced cancer. Atypical femoral fracture. Severe renal impairment or undergoing dialysis. Pregnancy & lactation. Childn. Lactation: Unknown whether drug is distributed in breast milk; caution is advised

Side Effects

• >10% Back pain (34.7%)
• Extremity pain (11.7%) 1-10% Musculoskeletal pain (7.6%)
• Hypercholesterolemia (7.2%)
• Cystitis (5.9%)
• Upper respiratory tract infection (4.9%)
• New malignancies (4.8%
• compared with 4.3% in placebo group)
• Sciatica (4.6%)
• Nonfatal serious infection (4%)
• Bone pain (3.7%)
• Anemia (3.3%)
• Upper abdominal pain (3.3%)
• Rash (2.5%)
• Flatulence (2.2%)
• Osteonecrosis of jaw (2.2%)
• Pruritus (2.2%)
• Hypocalcemia (1.7%) <1% Serious infection of abdomen resulting in hospitalization (0.9%)
• Serious infection of urinary tract resulting in hospitalization (0.7%)
• Serious infection resulting in death (0.2%)
• Pancreatitis (0.2%)
• Serious infection of ear resulting in hospitalization (0.1%)

Contra indication

Clinically significant hypersensitivity to denosumab or to any of the components. Hypocalcemia.

Pregnancy and lactation

Pregnancy category: X

Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.